Whalesbook
Vijaya Diagnostic Centre's board has approved its audited financial results for the fiscal year ended March 31, 2026. The company announced a recommended final dividend of ₹2 per equity share. It also completed the acquisition of the MRI, EEG, and NCV Services Business for approximately ₹4.20 crore. Additionally, 1,79,500 Employee Stock Options (ESOPs) were granted at an exercise price of ₹784 per option.
The board met on May 7, 2026, to review these results. While specific detailed financial figures for the year were not provided in the announcement, the recommended final dividend represents a 200% payout on the face value of the shares. This dividend is subject to shareholder approval at the upcoming Annual General Meeting (AGM).
The acquisition of the MRI, EEG, and NCV services business from Medinova Millennium MRI Services LLP aims to expand Vijaya Diagnostic Centre's service portfolio. The granting of ESOPs is part of the 'VDCL Employee Stock Option Plan 2018,' designed to incentivize employees and align their interests with the company's growth.
These corporate actions reflect active management and strategic expansion. The dividend offers a direct return to shareholders, while the acquisition is expected to broaden the company's diagnostic capabilities and potentially reach new patient segments. The ESOPs provide employees with a vested interest linked to the company's stock performance.
A key aspect to monitor is that the acquisition of the MRI, EEG, and NCV services business constitutes a Related Party Transaction (RPT). Such transactions are subject to stringent regulatory review under SEBI Listing Regulations and the Companies Act, 2013, requiring necessary disclosures and approvals to ensure fairness and transparency.
Investors will be watching for the official announcement of the AGM date and the record date for the dividend payment. Shareholder approval for the dividend and further disclosures regarding the RPT will be important updates.